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Early diagnosis of Borrelia burgdoiferi infection, hampered by 
the absence of detectable antibodies in most patients with 
erythema chronicum migrans is important to prevent late-
stage neurologic, rheumatologic, and skin disorders. Fur-
thermore, B. burgdoiferi has been claimed to be the causative 
agent in localized scleroderma (morphea). We used peR 
amplification to search for B. burgdoiferi outer surface protein 
OspA-specific sequences in DNA obtained from lesional 
skin biopsies on Finnish patients with clinically suspect ery-
thema chronicum migrans, lymphocytoma, morphea, or 
with diverse skin manifestations and persistent high antibod-
ies to B. burgdoiferi flagellar antigen. Seronegative patients 
with other skin lesions served as controls. The amplicons 
obtained with primers specific for B. burgdoiferi type strain 
B31 ospA sequence did not hybridize to the corresponding 
probes, and thus the DNA amplified from a Finnish B. burg-
doiferi erythema chronicum migrans skin isolate was se-
quenced. This 98-nucleotide sequence of ospA (332-429) 
showed 11 % to 14% nucleotide divergence compared with 
the North American type strain (B31), several European 
T he diagnosis of Lyme borreliosis is frequently im-peded by the fact that antibodies against the causative spirochete Borrelia burgdorferi are detected only in 30 to 60% of patients during the first 6 weeks of infec-tion, even if the primary skin symptom, erythema 
(chronicum) migrans (ECM), is present [1-3]. In an Austrian study 
based on extensive ECM patient material, only 17% and 25% of sera 
had raised IgM and IgG antibody titers to B. bllrgdorferi [4]. The IgM 
antibody response is often first seen after a few weeks of antibiotic 
therapy [5]. Lyme disease shows a complex range of clinical mani-
festations, from arthritis and neurologic disease to several types of 
skin lesions [6]. In addition to early-stage ECM, the skin lesions 
include lymphocytosis cutis benigna, diffuse erythematous lesions, 
and morphea-like sclerotic skin lesions and acrodermatitis chronica 
atrophicans (ACA) in the chronic phase [7 - 9]. In some patients 
with various other skin lesions, we often see persistently elevated 
antibodies to B. burgdorferi, and the significance and specificity of 
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strains, and an East Siberian tick strain. The sequence was 
almost identical (99%) to a Swedish isolate from acroderma-
titis chronica atrophicans. Using oligonucleotides specific 
for the Finnish strain, a positive polymerase chain reaction-
based hybridization was obtained in six of seven untreated 
erythema chronicum rnigrans patients infected in Finland or 
in Estonia, and in the lymphocytoma patient. Only two of 
the erythema chronicum migrans patients had IgG or IgM 
antibodies to flagellin. However, all seven morphea lesions as 
well as the other lesions were polymerase chain reaction 
negative. Polymerase chain reaction- based hybridization of 
B. burgdoiferi OspA gene from skin-derived DNA thus pro-
vides a sensitive and specific diagnostic tool. In conditions 
not unequivocally known to be caused by B. burgdoiferi, like 
in morphea, this assay was negative. We also demonstrate 
that peri-Baltic B. burgdoiferi isolates show homology in their 
OspA genes but differ from geographically more distant iso-
lates. Key words: Borrelia burgdoiferi/ OspA/ PCR/erythema 
chronicum/migrans/morphea. ] Invest DermatoI102:339-345, 
1994 
such antibodies remains to be resolved. Elevated antibody titers have 
also been demonstrated in localized scleroderma (morphea) [lO-
ll], altho~gh c~ntradictory findings have been reported [12 - 14]. 
In areas With a high prevalence of B. burgdorferi in ticks, a seropreva-
lence of 4-12%, depending on the method used, is observed in 
aSYI?ptomatic in~ividuals [15,16]. In Finland, the prevalence of 
poslt!ve ser<:>reactlOns I.S 12% in an adult population from an en-
demiC area 111 the archipelago of Turku, in southwestern Finland 
(Dr. 1. Seppa.la, University of Helsinki, Helsinki, Finland, personal 
commUI1l~atlOn), as a~ainst only 2.9% in the adult population in 
central F1I1land and 111 children of the Helsinki area (Dr. S. 
Kontiai~en, Aurora Hospital, Finland, personal communication) . 
The Isolation of B. bllrgdorferi from the blood or cerebrospinal 
fluid in borreliosis patients has often been unsuccessful. However, 
the spirochete can be cultivated from most ECM lesions [17,18] 
although the method is slow and complicated. Direct demonstra-
tion of B. bllrgdorferi from the tissue has been performed with a 
nonspecific silver staining method, and with monoclonal antibodies 
spe~ific for th~ outer surface protein A (OspA) of B. burgdorferi type 
stram B31 . With such methods, B. bllrgdotjeri has also been demon-
strated in some cases of morphea [19,20]. 
The use of polymerase chain reaction (PCR) for the amplification 
of scarce amounts of microbe-specific DNA from tissue or body 
fluid samples offers a sensitive and specific tool for diagnostic pur-
poses. Using the PCR technique and subsequent hybridization, as 
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littl e as 0.05 pg of purified B. burgdorferi DNA, corresponding to 
about 25 spirochetes, can be detected [21,22]. As the plasmid-en-
coded OspA gene is more specific for B. burgdorferi than the genus-
specific genomic flagellar gene [22-24], we generated oligonucle-
otide primers and probes specific for the ospA gene to look for B. 
bllrgdorferi DNA in skin biopsies of patients with ECM, morphea, 
lymphocytoma, and other dermatoses. 
The PCR and hybridization method enabled the demonstration 
of B. burgdorJeri-specific DNA in fresh skin biopsies ofECM and 
lymphocytoma lesions even when specific Borrelia antibodies were 
not present. We also show that Finnish B. burgdorJeri OspA se-
quences differ from those of other European strains and from the 
type strain B31. With primers and probes specific for the Finnish 
sequences, we were unable to demonstrate B. burgdorJeri - specific 
DNA in any of the seven morphea lesions. 
MATERIALS AND METHODS 
Patients and Tissue Samples Skin biopsies were obtained from 29 pa-
tients; nine patients presented with skin lesions clinically suspected to be 
caused by B. burgdorjeri infection, seven patients had freshly diagnosed cir-
cumscribed scleroderma lesions, five patients showed variable skin lesions 
and elevated antibody titers to Borrelia flagellin antigen, and eight patients 
had other dermatoses. The skin biopsy was always obtained from the active 
indurated or erythematous skin area and a neighboring biopsy was obtained 
for histopathologic examination. The demographic data on the patients are 
given in Tables 2-4. 
Antibodies to B. burgdorferi Antibodies to B. burgdorferi flagellar protein 
were routinely determined using the enzyme-linked immunosorbent assay 
(ELISA) method [3]. Primarily, IgG class antibodies were measured but if 
elevated titers were obtained, IgM antibodies were also measured. In this 
assay, antibody titer 500-1000 is regarded as possibly indicative of B. burg-
dorferi infection, and titers above 1000 are considered positive. During this 
study, the anti-flagellar antibody assay was routinely used in the hospital 
setting instead of previous less specific antibody assays based on whole cell 
extracts. 
Isolation of B. burgdorferi from ECM Skin Lesion DNA extracted 
from a Finnish B. burgdo rferi isolate, designated KS 1, was used as a positive 
reference in the PCR assays. The isolate originated from a skin biopsy of a 
typical ECM lesion on a leg. The spirochete was cultivated in Barbour-
Stoenner-Kelly medium [18] modified by substituting fetal bovine serum for 
rabbit serum and omitting antibiotics for 4 weeks. The isolate was electron 
microscopically inspected by Dr. Kari Hovind-Hougen at the National Vet-
erinary Laboratory, Del1mark, and was morphologically similar to those 
isolated from Swedish ECM and ACA patients [25]. 
For DNA isolation, the organisms were pelle ted by centrifugation at 
10,000 X g for 30 min at 37"C, washed (phosphate-buffered saline,S rnM 
MgCI2), lysed with non-ionic detergents (10 rnM Tris-HCI, 2.5 rnM 
MgCI2, 50 rnM KCI, 0.1 mg/ml gelatin, 0.45% NP40, 0.45% Tween-20) 
and digested with proteinase K (0.06 mg/ml, Sigma) at 58'C for 1 h. 
Extraction of DNA from Skin Biopsies The DNA for peR amplifica-
tion was prepared from frozen tissue samples using a non-iOluc detergent 
method described previously [26]. In addition, DNA was extracted from 
some samples by the conventional phenol-chloroform extraction method 
[27]. We found no difference between the two methods in the yield or 
quality of DNA. 
Primers and Probes for PCR Amplification Oligonucleotide primers 
were syntheSized With Militpore Cyclone-DNA-synthesizer using beta 
amidite chemistry. Three oligonu~leotides (OspA 2, OspA 3, and OspA 4) 
were derived from preVIOusly publtshed B. burgdorferi type strain B31 OspA 
sequences ([26], Table I) . One additional oligonucleotide OspA 7 was syn-
thesized locating between OspA 3 and OspA 4 (845-863, Genebank acces-
sion number X14407). OspA 2 and OspA 4 orOspA 3 and OspA4 were used 
as primer pairs. OspA 7 was used as a probe for the latter primer pair. 
Additionally, another set of OspA-specific primers, SNl and SN2, and a 
corresponding probe SN3 (Fig 1) were synthesized, all based on the type 
strain B31 sequences [22]. This set has been shown to be specific for North 
American isolates [22]. The SN amplicon obtained from the Finnish B. 
burgdorferi isolate was cloned and sequenced, and the more specific primers 
BB 1 (332 - 354) and BB2 (405 - 429), and an oligonucleotide probe, BB3 
(360 - 380, Genbank accession number X 14407), were synthesized. To con-
trol the quality of the DNA extracted from the skin biopsies, each sample 
was also ampl ified with primers specific for human p-globin gene [28). 
These amplicons were visualized by ethidium bromide staining of agarose 
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gels (2% N uSieve agarose and 1 % SeaKem agarose; FMC BioProducts, 
Rockland, ME) . By amplifying for the p-globin gene under same conditions 
as for OspA, we also controlled that no inhibitors of amplification were 
present. 
PCR-Based Amplification of B. burgdorferi-Specific DNA and Liq-
uid Hybridization to 32P-Labeled Probe Amplification was carried out 
in 50 ml volume in an automated thermal cycler (Techne PHC-2, Cam-
bridge, UK) in Taq DNA polymerase buffer containing 2.5 U Taq DNA 
polymerase (Gibco BRL, Gaithesburg, MD), 200 rnM dNTPs, 1 mM 
primers, and 1.5 mM MgCI2. The optimal amplification conditions for each 
primer pair were deternilned by adjusting the MgCI2 and primer concentra-
tions and cycling temperatures. For OspA primers, best results, using DNA 
extracted from the Finnish KSl B. burgdorferi isolate as a template, were 
obtained with the following amplification temperatures: 94 0 C l' 30",50' C 
l' 30", 72'C 2', repeated for 30 cycles. PCR amplification with SN1-SN2 
primer pair was performed successfully only under nonstringent conditions 
(94'C 30", 37 ' C 30", and 72 'C 1') for 40 cycles. For the primer pair 
BBI-BB2, specific for the Finnish KS1 isolate, cycles of94 'c 1', 60 ' C 30", 
and 72' C 30" repeated 25 times, were optimal. The optimal MgCI2 concen-
tration for the BB 1 + BB2 primer pair was 2 111M. The amplicon was sub-
jected to liquid hybridization to 32P-Iabeled specific oligonucleotide probe 
(1.25 pmol, 5 X 105 dpm/ml) at 55'C for 30 min. For the OspA and SN 
probes, hybridization was also attempted at 45'C. The hybridized product 
was electrophoresed through 10% polyacrylamide gel, and autoradio-
graphed. 
The PCR reactions were carried out in a laboratory specifically designed 
for PCR work to avoid carry-over contaminations. No Borrelia plasmids 
have ever been handled in this space, and the positive control samples were 
always pipetted last and in a different room with separate air conditioning. 
Positive-displacement pipettes were used, and the PCR reagents were stored 
in small aliquots and always handled in a separate room from the patient 
samples or amplified products. 
DNA Sequencing After 3% agarose gel electrophoresis of B. burgdorferi 
DNA amplified with SN1-SN2 primers, a piece of agarose gel containing 
DNA fragments of the expected length (145 bp [33]) was isolated. The 
DNA was purified with Sephaglas BandPrep Kit (Pharmacia, Sweden), 
treated with K1enow enzyme and ligated into Hinc II cleaved M13mp18 
vector [27]. Aft~r transformation, the recombinants were purified and se-
quenced accordmg to the Sequenase Version 2.0 protocol (United States 
Biochenilcals, Cleveland, OH). The B. burgdorferi sequences were analyzed 
for maximum homology with BESTFIT program (GCG sequencing analy-
sis software package [29]) , and no gaps were allowed. The final alignment 
was made with LINEUP program [29]. The OspA sequences of the follow-
ing B. burgdorferi isolates were compared to the Finnish sequence: the North-
American type strainB31, isolated from an I. dammi,ti tick in New York state 
(Genbank accessiml number X14407), East-Russian (Siberian) strain Ip90 
form I. permlcaws t.lck [37], S",:edlsh ACA patient skin isolate ACAI [17], and 
the European strams ZQ1 (tick Isolate from Germany; accession number 
X66065), Goe 2 (X60300), Pko skin isolate (X62161), and B29 isolate from 
I. riei,lus tick in Germany (M88764). 
RESULTS 
Identification of OspA Sequences Specific for Finnish B. 
burgdorferi .We first tried PCR amplification of the KS1 isolate 
and some patient samples with OspA 2, 3, and 4 primers. One pg of 
B. burgdorJeri DNA was successfully amplified (annealing tempera-
ture .50'C or b~low) with the OspA 3 and OspA 4 primer pair. The 
obtamed amphcon of the expected size of 119 bp in agarose gel 
electrophoresis did not yield detectable signal on the autoradio-
graphs when hybridized to either labeled OspA3 or OspA7 probe. 
The same samples were therefore also amplified with another 
primer pair, SNI and SN2. With this primer pair, we always ob-
tained an amplified DNA of the correct size (145 bp) both from the 
cultured isolate of B. burgdorJeri and from some patient samples. 
However, formation of nonspecific amplification products was 
common. We did not manage to eliminate these, even with "hot 
start" PCR or elevated annealing temperatures. No hybridization to 
the SN3 probe was obtained, even at low stringency. We therefore 
cloned the PCR amplification product obtained with the SNI + 
SN2 primer pair into M13mpl8 vector and sequenced it. 
The 98 nucleotide sequence of the Finnish B. burgdorJeri isolate 
KS 1 (Fig 1) differed in 11 nucleotides (11 %) from the North Amer-
ican B31 type strain, and in 13 to 14 nucleotides (13-14%) from 
published European B. burgdorJeri sequences [23] but in only five 
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Table I. B. br,lrgdorferi -Specific Oligonucleotide Primers and Probes Used" 
Finnish B. bllrgdotJeri Isolate 
Primers Probe Reference Amplification Hybridization 
OspA2: 889 - 1 003 OspA4: 758 -783 Persing DH, el ai, 1990 [34) +, weak 
OspA3: 876-851 
OspA4: 758- 783 OspA7: 815-833 + 
OspA3: 876-851 
Nielsen SL, el ai, 1990 [33] ++ SN1: 306-331 SN3: 360-394 
SN2: 450-427 
BB1: 332-354 BB3: 360-386 Ranki A, el ai, 1993 +++ +++ 
BB2: 405 - 429 
• Nucleotide locations refet to B. bllrgdorferi type strain B31 (Genbank accession number X14407) OspA sequence. 
nucleotides from a German skin isolate [30] and in 1 nucleotide 
from the Swedish ACA-1 isolate [31]. In the region of the SN3 
probe, there was a mismatch of seven nucleotides (20%) in the 
Finnish strain compared with the American type strain B31. We 
therefore synthesized a new set of primers (BB 1 and BB2, 332 - 354 
and 429-405, Genbank accession number X16467). Using these 
primers at annealing temperatures of 55-60°C in 25 PCR cycles, 
amplified DNA (98 bp) that hybridized to the internal probe BB3, 
was obtained from the Finnish ECM isolate KS1 (Fig 2, Table I). A 
significantly weaker signal was obtained when either SNl or SN2 
was used as the other primer (product of119 bp in Fig 2) . Under the 
same conditions, no hybridizing product was obtained with the type 
strain-specific SNl + SN2 primer pair alone (Fig 2). 
Amplification and Hybridization Results in Clinical 
Samples Altogether eight patients presenting with annular or 
large red, indurated skin lesions were clinically suspected of ECM. 
The diagnoses were confirmed histologically. The time between 
possible or documented tick bite and the biopsy varied from 2 weeks 
to about 6 months. One patient (number 6, Table II) had received 
cefalexine prior to the biopsy. Using the oligonucleotides specific 
for Finnish B. bu.rg~orferi strain, spec.ific ~N~ was s~ccessfully am-
plified and hybndlzed from the skm biopSies of SIX of the seven 
untreated ECM patients (Table II and Fig 3). Interestingly, only two 
of the patients had detectable antibodies (at suspicious level) to 
Borrelia flagellin antigen at the time of the biopsy for PCR (Table 
II) , and a third patient (number 8) had IgM class antibodies only. In a 
further patient, a rise in the antibody titer was observed only after 
treatment with amoxicillin. 
The PCR-based hybridization was negative in one ECM patient 
treated a month earlier and in another patient with a large ECM on 
the abdomen and thighs (Table II). It is possible that in the latter 
SN l BBl BB) 
1A:=w:I~M:A;rrrAliM:1ol&t:~TT~OA~QC~T~MMml!iGM~~CTT~CTCA~T. CMTGGTTCTQGQQT~ 
ell 306 CCATCTMTTGCM CAGTACACMGCTTGAGCTTAAAGGMCTTCTCATAAAMCMTGGATCTGGAGTACTTGA 
FIN92 1 - --- - --A- ----- -- --- - --- - - -0- - - -- --I- ----c--G- ----
.Ip90 192 -11.0-- - - --co-- - -- - -- - - -- - - - - - --- - -- - - ---- - -- --- - -- - - --- - - - -c- - T - -- -- -AC-- - - --
ACAI 192 -11.0- - - - -11.0-- -- --- - -- - - -- -11.- - -- -- - 11. - - - --- - - - - --- - - - - -G - - - - ---T- --- - - - -co-- ---
ZQ1 156 - AG- - --GAO- - - - --- - - - - ----- - - -- --- - - - - - - - - - -- - --- - - - - --- --C- - T -- -- - -AC--- ---
Goe2 300 - AG - - - - OAG- - - -- -- -- --- - - -G- ---- - --- - -- - - --- ---- - - - - --- ---C- - T - --- - -AC - - --.-
N40 156 - - - -- - - - -- - - - - --- - - - ---- - ---- ----- - -- -- - - -- -- -- - - - - -- - - -- - -- --- - - - - -- -- ----
Pko 216 -AG-- ---AG-- - - --- - - - -- -- -11.- -- -- - - 11. - - ---- - - - --- - -- - - -G- - - --- - I - - -- -G- -G- - - --
829 240 - 11.0- - -- 011. - -- ---- - - - ------ - - -- - - --- - - - -.-- - - -- - - - - - - -- --- -C- - T - - - -- - -C- - - ---
Bn' SN' 
3' - TCATTTTMl'TGTTMCQACTGCTA -S' 
831 381 AGGCGTAAAAGCTGACAAAAGTAAAGTAAAATTAACAA'M'TCTGACQATCTAGGTCAMCCACACTTOM 
FIN92 50 - - - TAC - - - - - 11.- - -- - - - --e- - - --- - - - --- --- ---e- --- - ---
Ip90 26 7 - - - I - A-- - - 11. -- - -- - - ---C- - - - - - - - - -- - - - ----0- ---0--- - - - 11.- - 11. - --- - - - - T- - ---
ACA~ 267 - - -TAC-- -- -11.- - - - - - - --e- -- - - - - - - --- - - - - - -0- - - - -- - - - - - 11.- - 11.- - - -- -- - T --- --
ZQ1 231 - - - I-A- - - - 11.--- -- - --- - - - - - -- - ----- - - -- - - -G- - - -G- -- - --11.- - 11.- ---- -- - T - - - --
Goe2 375 - - - I - A - - - - 11. -- - -- - -- - - - -- -- --- - - - - - - - -- - -0- ---I- -C- --11.- - - - - -- I - A-T- -- --
"40 231 ------------- --- ---------------- - ----- - -- -- -------- --- -- --- ---------- -
Pko 291 - --I-C-- - - - 11.- - - - - - - -- - - - - -e- ----- ---- - --0- -- -- - - -- - - 11.- - A - - - - --- - T -C- --
829 315 - - - I-A - - --A - - - - - -- - - - - - --- - - --- - - -- - ----G-- - -I--C- --A-- - - ---T - A-I--- --
Figure 1. Nucleotide sequence (FIN) of the ospA gene region 332-429 of 
Finnish B. bllrgdo1eri isolate KSI in comparison to North-American (B31 
type strain), East-Russian (Ip90), Scandinavian (ACAI), and Middle-Euro-
pean (ZQI, Goe2, Pko, B29) strains. The primers (BDI and BB2) and probe 
(BB3) based on the Finnish sequence are shown. 
case the biopsy was not obtained from an area with spirochetes. A 
third patient, who presented with an erythematous ECM-suspect 
lesion on the arm and who had spent the summer in Austrian alps, 
was also PCR negative (Fig 3) . He might have been infected with a 
non-homologous B. burgdorferi strain. 
In this series of patients, a 3-year-old boy presented with a scrotal 
lymphocytoma (Table II). The biopsy of this lesion gave a strong 
positive PCR-based hybridization signal for B. btlrgdorferi. The boy 
was subsequently treated with amoxicillin, and the lesion resolved 
completely. 
The specificity of the BB1, BB2, and BB3 sequences was con-
firmed when no B. br~rgdorferi-specific DNA was detected in eight 
other patients with skin lesions not typical of or not suggestive of 
borreliosis (Table III). None of these patients had raised antibody 
titers to flagellin. Histopathology revealed various other dermatoses 
in all these patients. 
Skin biopsies from six patients with high antibodies to B. burgdor-
Jeri but with diverse skin manifestations were also studied (Table 
IV). One patient presented with localized scleroderma. She received 
intravenous ceftriaxone treatment (2 g/ d for 14 d), but there was no 
change in the antibody titer 4 months later. Three other patients 
had received extensive previous antibiotic therapy, either with oral 
penicillin or with intramuscular ceftriaxone, for a suspected borre-
liosis. None of the patients had anti-cardiolipin antibodies. At the 
time of the biopsy for the PCR analysis, the histopathologic analysis 
did not reveal any changes suggestive of ECM or ACA in any of the 
patients. All these patients were negative in the PCR analysis with 
the Finnish primers and probe. Despite this, all patients received 
antibiotic treatment (ceftriaxone intravenously for 14 d, amoxicil-
lin for 3 months, or doxycycline for 1 to 3 months), but no decrease 
in antibody titers was seen in three of four patients during follow-up 
(Table IV). 
When skin biopsies of the active borders of altogether seven 
patients with histologically confirmed morphea (Tables III and IV) 
were analyzed with the PCR method using either oligonucleotides 
based on the Finnish ospA sequence or those based on the type-
strain sequence, no hybridization signal was obtained (Fig 4). The 
results were negative even when low stringency or repeated analyses 
were performed. 
DISCUSSION 
We demonstrate that the Finnish B. burgdorferi strain, isolated from 
an ECM skin lesion, shows genetic heterogeneity in its OspA in 
comparison with B. burgdorferi isolates from other geographic areas. 
Due to this heterogeneity , the demonstration of B. burgdorferi-
specific DNA of skin biopsies from other Finnish patients was suc-
cessful only after the partial sequence of the ospA gene in the native 
B. bllrgdorferi was identified. 
There has been a need for the accurate demonstration of B. blirg-
dorferi spirochete in early infections, in which an antibody response 
to the flagellar antigen is detected only in 36 - 70% of cases [3]. As 
borrelial flagella resemble those of other treponemes and other 
gram-positive bacteria [25], the specificity of the antibody test has 
also been a problem sometimes. Also, it has become evident that not 
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Figure 2. Hybridization of a Finnish ECM B. burgdorferi isolate and ofECM skin lesion-derived DNA samples to 32P-labeled oligonucleotide probe (BB3), 
based on the Finnish OspA sequence, after PCR amplification with primers based on North-American type strain (SN1, SN2) or the Finnish OspA (BBI, 
BB2) nucleotide sequences. ECMI and ECM3 denote patients in Table II. 
only erythema chronicum migrans but also some atypical ery-
thematous skin lesions, as well as benign cutaneous lymphadenosis, 
morphea-like skin lesions, and even lichen sclerosus et atrophicus, 
may be associated with borreliosis [7 -9]. 
PCR amplification of the plasmid-encoded OspA gene has been 
previously shown to be highly specific for B. burgdorferi [24], as the 
linear plasmid coding for OspA is not found in other procaryotic 
organisms [32]. The OspA protein, which is exposed on the surface 
of the microbe unlike flagellin, is of special interest as it is associated 
with the virulence of the spirochete [32,33], and, also, as it is the 
major target of a protective immune response [34-36]. Using 
primers and corresponding probes first from the C-terminal part of 
Table II. Detection of B. burgdorferi OspA-Specific DNA by PCR Amplification and Hybridization in Comparison 
with Serologic Findings 
Clinical 
Diagnosis 
1. ECM 
2. ECM 
3. ECM 
4. ECM 
5. ECM 
6. ECM, 
status post 
7. ECM 
8. ECM 
9. Lymphocytoma 
PCR-Based 
Hybridization Result' 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
Anti-Flagellar Antibodies 
(time after PCR) 
Negative' 
Negative (2 months) 
Suspicious 
Negative (up to 5 
months) 
Negative 
Positive (1 month) 
Negative (5 mOllths) 
Positive 
Suspicious (3 weeks) 
Positive (5 months) 
Negative 
Negative (1 month) 
Suspicious 
Negative (up to 3 
months) 
Negative 
Suspicious 
Suspicious 
• Oligonucleotides specific for the Finnish strain of B. bllrgdorferi were used. 
Treatment Historyb 
Tick bite 3 weeks earlier; doxycycline 14 d -+ cured 
Amoxicillin 2 weeks -+ cured 
Tick bite 5 months earlier; amoxicillin 2 weeks -+ cured 
ECM in buttock for 2 months; amoxicillin 1 month -+ cured 
ECM in lower abdomen for 1.5 months; penicillin 3 
weeks -+ cured 
ECM I month earlier: cefalexine 10 d; doxycycline 10 d-+ 
cured 
Tick bite in Estonia 2 - 3 weeks earlier 
Tick bite 2-3 weeks earlier 
Lesion for 2 months in scrotum, amoxicillin 3 weeks ..... cured 
, Dosages used: doxycycline 200 mg/d orally, amoxicillin 2 g/d orally (children 40 mg/kg), ceftri.xone 2 g/d intravenously . 
, Neg.tive indicates ELISA titer below 500, suspicious = titer 500 - 1000, and positive = titer above 1000. 
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B.b. DNA 
neg DNA 
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Figure 3. PCR amplification and hybridization results of skin DNA sam-
ples from three ECM patients, one patient suspected for ECM, one with 
morphea, and one with panniculitis. The Finnish ECM isolate KS-l (desIg-
nated B.b. DNA) served as a positive control. 
the ospA sequence and then from.the N-terminal part, we obtained 
amplified DNA of t~e correct size. from DNA extracte~ fro.m .a 
Finnish B. burgdorferi Isolate, and estImated that the detectIOn lImit 
was 0.01 pg. A similar quantity of HIV DNA was amplified in 
parallel experiments, and other groups have been able to amplify the 
same amount of target DNA with B. burgdorferi-specific chromo-
somal primers [21]. However, we were unable to hybridize the 
amplified DNA, even under low-stringency conditions to probes 
deduced from the type strain B31 sequence. We therefore cloned 
and sequenced the amplified product. 
The 98 nucleotide sequence of the Finnish ECM isolate, KS1, 
Table III. Detection of B. burgdorferi-specific DNA by PCR 
Amplification and Hybridization in Skin Biopsies of 
Circumscribed Scleroderma (morphea) and in Other Dermatoses 
in Relation to Serologic Findings 
Patient Group 
Morphea 
Other dermatoses' 
Condylomata 
acuI11inata 
Number of 
Patients 
6 
5 
3 
PCR-Based 
Hybridization 
Results' 
Negative 
Negative 
Negative 
Anti-Flagellar 
Antibodies' 
<200-580 
<200 
Not determined 
• O ligonucleotides BBI , BB, and BB3 specific for the Finnish B. burgdo1eri were 
used. 
, Based on repeated measures. 
, Includes eczema, lupus erythematosus, melanosis, plasma cell infiltrate. 
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OspA gene (FIN) showed equal nucleotide divergence (11 to 14%) 
from the North American type strain (B31), from GermanI. ricinus 
tick isolates (ZQ1, B29) and from an East Russian (Siberian) 1. 
persulcatus-tick isolate (lp90) [31,37]. The FIN sequence showed 
most (six of 30, 20%) diversity in the region for which the type 
strain-based oligonucleotide probes were designed and this would 
explain the negative hybridization results. It is of interest to note 
that there was only one to five nucleotide differences in FIN com-
pared with sequences available from two other borreliosis skin iso-
lates, namely, the geographically close Swedish acrodermatitis 
chronica atrophicans isolate ACA-1 and a German skin isolate Pko 
[17,30]. The two latter isolates fall into the same branch in the 
phylogenetic tree, based on amino acid homologies [23], and they 
are most distant from the North American strains. Thus, it is possi-
ble that geographical difference in the clinical syndromes of Lyme 
borreliosis would be reflected in genomic variability of the OspA, as 
in Europe ECM lymphocytoma and ACA are the prevalent symp-
toms and in the United States arthritis is more common. 
Using the new set of oligonucleotides based on our native ospA 
sequence, we obtained a strongly positive PCR result, conlirmed by 
hybridization to a specific probe, in six of the seven untreated ECM 
lesions and in the one lymphocytoma lesion. It is noteworthy that 
only two of these patients had antibodies to B. burgdoiferi f1agellin at 
the time of the biopsy. However, one additional ECM patient, 
treated with cefalexine 1 month earlier, gave a negative PCR result. 
Our results thus extend the recent findings of Melchers and co-
workers [38] and Schwarz and co-workers [39] . The first group 
found B. burgdoiferi-specific DNA after application of nested 
primers specific for the genomic DNA, in three of four skin biopsies 
from ECM patients and in most ACA lesions, but not in a morphea 
lesion. However, the use of a single set of primers, like in our 
method, instead of nested PCR is always much safer in a clinical 
diagnostic setting when carry-over contamination of the samples 
must be avoided. Schwartz and co-workers [39], using primers and 
probes specific for the 23S rRNA sequences, achieved a sensitivity 
of 59 to 62% in demonstrating B. burgdorferi in 35 untreated ECM 
skin lesions. However, their PCR method was positive in only nine 
of 19 seronegative ECM patients although B. burgdoiferi isolates 
from three geographically distant areas were positive with the assay. 
Our Finnish isolates have not yet been tested with these 23S rRNA 
primers. 
All the samples of ours other than the ECM patients, including 
those with morphea, gave a repeatedly negative PCR result. As the 
morphea samples were also negative with the type strain-specific 
primers., even under low stringency, it is unlikely that a B. burgdorferi 
strain different from the geographically typical strain was present in 
the morphea lesions. We were thus unable to confirm previous 
findings, based on serology, immunohistochemistry, or nested PCR 
with genus-specific flagellar primers, of an association between B. 
burgdorferi and morphea [10,11,40,41]. It may, however, be possible 
that morphea is caused by another B. burgdorferi strain with either a 
divergent or a completely missing ospA gene. 
The group of patients with persistently elevated antibody titers to 
Borrelia flagellin and with various skin lesions were perhaps the 
most cumbersome in terms of clinical decision making. In all these 
patients, most of whom had previously received antibiotic treat-
ment for a suspected borreliosis, the PCR results were completely 
negative. The possible reasons for the negative result, despite sus-
tained anti-flagellin antibody response, are that in some patients a 
prolonged serological scar might survive after a borrelial infection, 
or that the number of spirochetes in the lesions was below the 
detection limit of our method, or that a strain with considerably 
divergent ospA gene was the causative agent. Our findings would 
favor the first possibility as the patients did not develop any symp-
toms typical of borreliosis during a follow-up of up to 2 years. 
In conclusion, we have shown that a peR method, applied di-
rectly to skin biopsy samples, is a reliable diagnostic tool for early 
borreliosis even when a specific antibody response is lacking. We 
also show that the ospA gene, coded by a linear plasmid typical for 
B. burgdorferi, found in Finnish B. burgdorferi skin isolates differs 
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Table IV. Results of PCR Amplification and Hybridization of B. bllrgdorferi OspA-Specific DNA in Skin Biopsies of Patients with 
Persistently Elevated Antibodies to B. burgdorferi Flagellin in Relation to Therapeutic Efforts 
Patient Clinical Diagnosis 
K.H Morphea 
GE Panniculitis 
ES Hyperpigmentcd 
macules 
MR SCLEb, suspected 
RB LSN 
VK Anetoderma 
PCR-based 
Hybridization' 
Anti-Flagellar Antibodies 
(follow-up time in months) 
710 
1000 (4) 
1200 
2600 (2) 
3400 
3300 (1) 
5600 (4) 
3800 (6) 
6100 (10) 
2060 
560 (1.5) 
880 (10) 
2000 
Lost to follow-up 
8710 
7100 (2) 
4400 (5) 
7100 (11) 
2400 (16) 
270 (20) 
Treatment History 
Previous antibody titers: 1600- 2700, several penicillin 
treatments; -+ ceftriaxone 2 g/d intravenously, 14 d 
Borreliosis treated 7 months earlier, whereafter anti-
body titer 4000, penicillin 1 month prior to biopsy 
Penicillin 2.5 month earlier, -+ doxycycline 
200 mg/ d, 3 months 
-+ ceftriaxonc 2 g/d intravenously, 14 d + amoxicillin 
1.5 g/d, 3 months 
Prednisone 40 mg/d 2 wceks earlier, -+ tetracycline 
1 g/d, 3 weeks 
-+ tetracycline 1 g/ d, 3 weeks 
Ceftriaxone 2.5 g/ d intramuscularly, 12 d 
-+ doxycycline 200 mg/d, 1 month 
• Oligonucleotides specific for the Finn.ish type of B. burgdorferi were used. 
• SCLE, subacute cutaneous lupus erythematosus; LSA, lichen sclerosus et atrophicus. 
from that of other European and North American isolates. The 
genetic heterogeneity of B. burgdorferi isolates has been recently 
disclosed [4,30,42-44] . The isolates can be grouped into six differ-
ent ospA genotypes, five of which are found among European iso-
lates, whereas American isolates almost exclusively fall into one 
group only and show sequence homologies of> 99% [23]. Most 
amino acid divergence has been described in the middle region and 
in the C-terminal half of OspA [36,44], but the Finnish sequence 
clearly covers a more N-terminal region. It is noteworthy that we 
were able to demonstrate B. burgdorferi-specific DNA with oligo-
nucleotides specific for the Finnish strain also in a skin lesion result-
ing from a tick bite in Estonia, and the Finnish ospA sequence was 
almost identical to that of the Swedish ACA isolate. Thus, it seems 
that the B. burgdorferi isolates around the Baltic sea are closely re-
lated. 
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Figure 4. B. burgdorreri ospA-specific peR amplification and hybridization 
results of morphea skin samples with oligonucleotides specific for the Fin-
nish strain. 
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